Physician profile
Matthew Alan Johnson
NPI 1881105914
$1,113.00
in general payments reported to CMS, 2019-2025
15 companies · $181 in 2025
The $181 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2021: $138 · 2022: $197 · 2023: $120 · 2024: $240 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $540.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $243.12 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $136.81 | 2024 | Infuse, Xiidra, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $106.15 | 2019 | |
| Aerie Pharmaceuticals, INC. | $99.22 | 2021 | |
| Oyster Point Pharma, INC. | $88.00 | 2022-2024 | Tyrvaya |
| Abbvie INC. | $85.64 | 2023-2025 | |
| Alcon Vision LLC | $72.32 | 2025 | Tryptyr, Rocklatan |
| Sun Pharmaceutical Industries INC. | $65.96 | 2022-2024 | |
| Horizon Therapeutics Plc | $56.83 | 2022-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $37.28 | 2024 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $37.00 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $34.99 | 2025 | Acthar |
| Shire North American Group INC | $20.00 | 2019 | |
| Heidelberg Engineering, INC. | $15.19 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $14.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.